GWGovind Warrier

Govind Warrier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Govind Warrier has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Loneliness in Daily Life by Combining Ecological Momentary Assessment and Passive Sensing: Scoping Review (Preprint)

    by Hyeonjin Cho, Mangyeong Lee, Jungin Joo, Sookyung Won, Jiyoon Han, Doyeon Kim, Govind Warrier, Johannes Thrul, Juhee Cho

    BACKGROUND Loneliness fluctuates with daily social context, yet is typically assessed with retrospective questionnaires. Combining ecological momentary assessment (EMA) with passive sensing from smartphones and wearables could capture loneliness and its behavioral and physiological correlates in daily life, but how these methods have been integrated has not been mapped. OBJECTIVE This scoping review aimed to map how loneliness and related social constructs have been measured in studies combining EMA and passive sensing, including EMA sampling schemes, sensing devices, and the temporal alignment of the two data streams, and to synthesize the reported associations between EMA-measured constructs and sensor-derived behavioral and physiological indicators. METHODS This review followed the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). We systematically searched PubMed, Embase, CINAHL, Web of Science, and PsycINFO from inception to January 13, 2025, and included studies of participants of any age, gender, or health condition. Eligible studies assessed (1) loneliness or loneliness-related constructs, such as social isolation, social support, and social interaction assessed via EMA; and (2) behavioral or physiological patterns in daily life, such as physical activity, sleep, heart rate, and phone use, captured via passive sensing. Data were charted with a standardized form capturing EMA and passive sensing methods and reported associations. RESULTS Of 157 records identified (86 after duplicate removal), 12 studies met the inclusion criteria, including 2 identified through backward citation chaining. All studies employed time-based EMA sampling, with study durations ranging from 3 days to 8 weeks. EMA measures primarily assessed loneliness, social contact, and social support. Passive sensing data were collected mainly via wearable devices (n=7) or smartphones (n=3), with only two studies integrating both platforms. Sensor modalities included physical activity, sleep, heart rate and heart rate variability, GPS-derived location metrics, and communication logs. Overall, more physical activity and less sedentary behavior were associated with lower momentary loneliness or greater social support. In contrast, findings for location-based metrics were mixed: visiting a greater number of unique locations was associated with lower loneliness, whereas stronger daily routines were linked to increased time spent alone. Communication patterns also differed by modality, with phone calls, but not text messaging, showing associations with lower momentary loneliness. Associations involving sleep and heart rate variability depended on individual or momentary characteristics, such as trait loneliness or concurrent rumination. CONCLUSIONS Research integrating EMA and passive sensing for loneliness assessment remains limited but shows promise for capturing its dynamic and context-dependent nature in daily life. Future studies should extend observation periods, integrate smartphones and wearables, incorporate more fine-grained contextual measures, and apply advanced analytic approaches to model within-person dynamics. These advances may enable more precise real-time assessment and support personalized interventions for loneliness.

  • Open Access

    AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery

    by Elizabeth M Will, Benjamin F Green, Scott Carey, Govind Warrier, Tricia R Cottrell, Aasheen Qadri, Andrew Jorquera, Sigfredo Soto-Diaz, Daphne Wang, Joel C Sunshine, et al.

    Background: The biological sciences are producing increasingly larger datasets for biomarker discovery. While common data models have been developed for medical terms as they relate to patient health outcomes, a data model that supports longitudinal tracking of biospecimens and relating them against an individual patient experience is a large, unmet need. Method: A structure and associated taxonomy were achieved through a six-tier build in Research Electronic Data CAPture (REDCap), which organizes the complexity of the therapeutic decisions, biospecimens, and outcomes that characterize a longitudinal patient experience. Modules were developed to support export of REDCap data into a Structured Query Language (SQL) format for merging with extended biomarker data, also housed in SQL. Results: The resultant AstroID resource is a relational structure for clinical and biospecimen data that meets several desired goals: searchable, flexible, generic, Health Insurance Portability and Accountability Act-compliant, auditable, and easy-to-use. The essential elements forming the core of the six-tiered build are provided, so others can readily adopt this schema, as well as an example of an extended, customized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support biomarker discovery and development are described, and example queries of the database are also presented. To the extent possible, the data dictionary was aligned with large data models, such as those for the National Institutes of Health’s Human Tumor Atlas Network. The structure can readily scale to accommodate thousands of patients, multimodality data, and spatial characterization of billions of cells. Radiologic imagery can also be included along with pathology imagery to support spatial studies, including artificial intelligence-driven analyses. Conclusions: This effort provides a database model for investigators conducting research on large volumes of biospecimens with clinical annotation. We have now deployed this structure in our laboratories and have over 1B cells spatially mapped, each effectively tagged with the clinical information from longitudinal patient experiences. While the description uses the example of cancer biomarkers, this data structure could be used to characterize longitudinal biospecimens from any disease process. In the near future, automatic synchronization between the electronic medical record and one or more AstroID databases is anticipated.


  • Open Access

    International real-world study of combination immunotherapy sequences in metastatic melanoma

    by Mora Guardamagna, Sarah E Lochrin, James William Smithy, Michael Postow, Caroline Gaudy-Marqueste, Nausicaa Malissen, Sandrine Monestier, Ryan J Sullivan, Juliane A Czapla, Aleigha R Lawless, et al.

    Background: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods: This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results: The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions: Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.


  • Open Access

    Boosting Physical Activity Among Individuals With Low Engagement Through Double-Point Incentives in a Community-Based mHealth Intervention: Retrospective Observational Study

    by Jungin Joo, Mangyeong Lee, Junghee Yoon, Hyeonjin Cho, Govind Warrier, Johannes Thrul, Juhee Cho

    Background: The administration of incentives to promote physical activity, such as the amount or timing, can vary depending on target health behaviors, research settings, intervention delivery channels, and participants’ preferences. Interventions implemented at scale necessitate the consideration of potential fiscal constraints for public health promotion. Since limited funding is a barrier to implementing community-based interventions, examining both immediate and sustained effects of temporary incentive increases on physical activity is important. Objective: This study aimed to evaluate the effect of a 1-week double-point event on increasing physical activity among low-engaged individuals in the context of a community-based mobile intervention. Methods: Using retrospective data from a Seoul Metropolitan Government mobile health (mHealth) intervention, we evaluated the effects of a 1-week double-point incentive on participants’ physical activity. During 3 registration phases from November to December 2021, a total of 50,145 individuals enrolled. Our analysis focused on the low-engaged group (n=27,833, 55.5%), who averaged fewer than 3 days per week of meeting the daily step challenge (at least 7000 steps) before the intervention. We performed a segmented regression analysis to assess changes in physical activity before and after the event. Multivariable logistic regression and Cox proportional hazards models were used to identify factors associated with improving and maintaining physical activity after starting the intervention. Results: Of 27,833 low-engaged participants, only 13.7% (n=3835) improved their physical activity. Daily challenge engagements per week increased by 2.53 times, and average daily steps increased by 1924.97 (standardized mean difference 0.55, 95% CI 0.51‐0.58). In multivariable logistic regression, older age was significantly associated with improved physical activity immediately after starting the intervention. However, 50% (1918/3835) of the improved group was likely to return to low engagement 3 weeks after the intervention ended. Older age and use of certain wearable devices were associated with maintaining physical activity after the intervention. Conclusions: Double-point incentives in the short term may serve as a cue-to-action to motivate low-engagement targets; however, they do not seem to guarantee long-term maintenance in the context of community-based mHealth interventions. Further research is needed to identify additional strategies beyond monetary incentives to sustain long-term healthy behavior.


  • Open Access

    Understanding Inequalities in Mobile Health Utilization Across Phases: Systematic Review and Meta-Analysis

    by Seongwoo Yang, Myoung Jin Cha, Robin van Kessel, Govind Warrier, Johannes Thrul, Mangyeong Lee, Junghee Yoon, Danbee Kang, Juhee Cho

    Background: Mobile health (mHealth) holds promise for enhancing patient care, yet attrition in its use remains a major barrier. Low retention rates limit its potential impact, while barriers to accessing or adopting mHealth vary across populations and countries. These differences in utilization of mHealth may exacerbate health inequalities, contributing to the digital health divide. Objective: We aimed to conduct a systematic review and meta-analysis to investigate the factors associated with inequalities in mHealth utilization across different implementation phases, including access, adoption, adherence, and maintenance. Methods: This systematic review and meta-analysis analyzed mHealth research from 2000 to May 30, 2024, using databases, including PubMed, Web of Science, MEDLINE, and ProQuest. Eligible studies included smartphones, mHealth apps, wearables, and inequality indicators across 4 mHealth phases: access, adoption, adherence, and maintenance. Excluded studies were nonpeer-reviewed, opinion-based, or not in English. Extracted data included study characteristics, target populations, health outcomes, and inequality factors like age, gender, socioeconomic status, and digital literacy. Factors were categorized using a digital health equity framework (biological, behavioral, sociocultural, digital, health care system, and physical domains). Meta-analyses were performed using a random-effects model for factors reported in at least three studies, with heterogeneity assessed by the I² statistic. Results: Among 1990 studies, 62 studies met the inclusion criteria, and 30 studies underwent meta-analysis. The phases of mHealth utilization were access (n=23, 37%), adoption (n=47, 76%), adherence (n=9, 15%), and maintenance (n=2, 3%). Meta-analysis showed older age was negatively associated with mHealth adoption (odds ratio [OR] 0.47, 95% CI 0.23‐0.93), while higher education and income were positively associated in both access and adoption phases. Employment showed significant associations in the access phase (OR 1.49, 95% CI 1.08‐2.05), whereas comorbidities (OR 1.39, 95% CI 1.03‐1.86) and private insurance (OR 1.63, 95% CI 1.07‐2.48) were significantly associated with adoption of mHealth. Women (OR 1.24, 95% CI 1.06‐1.45) and physically active individuals (OR 1.64, 95% CI 1.07‐2.50) were more likely to adopt mHealth. Conclusions: The conceptual framework outlined in this study highlights the multifaceted nature of mHealth utilization across all the phases of mHealth engagement. To address these inequalities, tailored and personalized interventions are required at each phase of mHealth utilization. Targeted efforts can enhance digital access for older and low-income adults while promoting engagement through education, insurance support, and healthy behaviors, thereby promoting equitable and effective mHealth use. By recognizing the interconnectedness of these domains, policy makers and health care stakeholders can design interventions that not only address the phase-specific barriers but also bridge broader inequalities in health care access and engagement.


  • Open Access

    Boosting Physical Activity among Individuals with Low Engagement through Double-Point Incentives in a Community-Based mHealth Intervention: A Retrospective Observational Study (Preprint)

    by Jungin Joo, Mangyeong Lee, Junghee Yoon, Hyeonjin Cho, Govind Warrier, Johannes Thrul, Juhee Cho

    BACKGROUND Community-based mHealth interventions for physical activity are being implemented in many countries; however, maintaining user engagement remains challenging. Therefore, the impact of additional short-term monetary incentives on low-engaged (LE) participants needs to be elucidated as a potential alternative. OBJECTIVE This study aimed to evaluate the effectiveness of an additional financial incentive, specifically a double-point event, within a community-based mHealth intervention designed to increase physical activity among individuals with low engagement. METHODS Using retrospective data from a Seoul Metropolitan Government mHealth intervention, we evaluated the effects of a one-week double-point incentive on participants’ physical activity. During three registration phases from November to December 2021, 50,145 individuals enrolled. Our analysis focused on the LE group (n=27,833, 55.5%), who averaged fewer than three days per week of meeting the daily step challenge (at least 7,000 steps) before the intervention. We performed a segmented regression analysis to assess changes in physical activity before and after the event. Multivariable logistic regression and Cox proportional hazards models were employed to identify factors associated with improving and maintaining physical activity after starting the intervention. RESULTS Out of 27,833 LE participants, only 137% (n=3,835) improved their physical activity. Daily challenge engagements per week increased by 253 times, and average daily steps increased by 192497 (SMD=0.55, 95% CI: 0.51-0.58). In multivariable logistic regression, older age was significantly associated with improved physical activity immediately after starting the intervention. However, 50% of the improved group was likely to return to low engagement three weeks after the intervention ended. Older age and use of certain wearable devices were associated with the maintenance of physical activity after the intervention. CONCLUSIONS Double-point incentives in the short term may serve as a cue-to-action to motivate low-engagement targets; however, they do not seem to guarantee long-term maintenance in the context of community-based mHealth interventions. Further research is needed to identify additional strategies beyond monetary incentives to sustain long-term healthy behavior

  • Durable tumor regression and restoration of neurologic function after treatment with anti-PD-1 in patients with functionally unresectable cutaneous squamous cell carcinoma with perineural spread into the cavernous sinus

    by Andrew R. Carey, Govind Warrier, Jenny K. Hoang, Megan D. Schollenberger, Evan J. Lipson, Nicholas R. Mahoney

    Purpose To describe tumor response and cranial nerve function outcomes after administration of anti-PD-1 to patients with cutaneous squamous cell carcinoma (CSCC) with perineural spread to cranial nerves (CN) extending into the cavernous sinus. Methods Electronic patient records from a single institution were queried for patients with CSCC of the head and neck causing diplopia (ICD-10 H53.2) who were treated with anti-PD-1. Data extracted included demographics, duration of anti-PD-1 therapy, immune-mediated adverse reactions, tumor response per adapted RECIST v1.1, and changes in CN function and symptoms (e.g., pain). All patients were prescribed cemiplimab 350 mg IV q3 weeks. Results Four patients met inclusion criteria. They had varying degrees of pain and sensory deficits in branches of the trigeminal nerve (CN V). One, 2, 3 and 1 patients had baseline involvement of CN III, IV, VI and VII, respectively. MRI confirmed perineural cavernous sinus involvement in all patients. Duration of anti-PD-1 therapy ranged 15–60 weeks. All patients experienced an objective anti-tumor response to anti-PD-1; partial response n = 2, complete response n = 2. At a median follow-up of 22 months, responses were ongoing in all patients. All patients demonstrated improvement in ocular motility deficits and pain with resolution of symptoms in 3 and 1 patients, respectively. Conclusion Administration of anti-PD-1 to patients with CSCC with perineural spread into the cavernous sinus can generate durable anti-tumor regressions and restore CN function, while sparing the morbidity associated with surgical resection and/or radiotherapy. Our findings add to emerging literature supporting this treatment approach for this patient population.


  • Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with vemurafenib.

    by Govind Warrier, Lilibeth Lanceta, Yoannis Imbert-Fernandez, Jason Alan Chesney

    E21005 Background: Increased glucose metabolism is a hallmark of neoplastic cells that allows self-promotion of growth and survival. The enzyme 6-phosphofructo-2-kinase (PFKFB3) is an integral controller of glycolysis by promoting the synthesis of fructose 2,6-bisphosphonate (F2,6BP) which activates 6-phoshofructo-1-kinase (PFK-1), a rate-limiting enzyme and essential control point in the glycolytic pathway. Additionally, mitogen-activated protein kinase (MAPK) is a key signaling pathway in a number of cancers with mutations of the BRAF component, described most commonly in melanoma, resulting in constitutive activation of the MAPK pathway. We aim to demonstrate that vemurafenib, a BRAF inhibitor, has antiglycolytic activity in sensitive melanoma cell lines which may help guide development of future therapies with specific attention to PFKFB3 as a potential enzymatic target to decrease glycolytic flux thereby inhibiting tumor growth and survival. Methods: Vemurafenib sensitive and resistant variants of two separate human metastatic melanoma cell lines (451Lu and WM983) were treated with 3 mM Vemurafenib for 24 and 48 hours. Additionally, cells from aforementioned lines were probed for PFKFB3 after 24 hours of treatment with vemurafenib. Glycolysis was measured by incubating cells in complete media containing 1 mCi [5-3H]glucose for 60 minutes. [3H]H2O produced by glycolysis through enolase was measured. Results: A decrease in PFKFB3 protein expression was found in vemurafenib sensitive cells compared to controls but not in resistant cells after 24h treatment with 3 mM vemurafenib in both 451Lu and WM983 metastatic melanoma cell lines (n = 2). Treatment with vemurafenib led to decrease in glycolysis compared to untreated controls in both vemurafenib sensitive metastatic melanoma cell lines but not in resistant cell lines (n = 5). Additionally, there was a significant reduction in glycolysis in vemurafenib resistant WM983 at 48 hours compared to resistant untreated control. Conclusions: BRAF mutated metastatic melanoma cells showed decrease in PFKFB3 protein expression and decreased glycolysis after treatment with BRAF inhibitor vemurafenib. Future studies will focus on assessing metastatic melanoma cell viability and glycolytic activity after treatment with combination BRAF inhibition and PFKFB3 specific inhibition.